A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients with Locally Advanced Gastric Cancer
Latest Information Update: 26 Dec 2024
Price :
$35 *
At a glance
- Drugs Zolbetuximab (Primary) ; Docetaxel; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms NEO-CLAUD
- 18 Dec 2024 New trial record